These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 30512992)

  • 1. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loco-regional staging of malignant pleural mesothelioma by integrated
    Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
    Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
    Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
    Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
    AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
    [No Abstract]   [Full Text] [Related]  

  • 5. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
    Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Diagnostic Accuracy for TNM Stage Among Whole-Body MRI and Coregistered PET/MRI Using 1.5-T and 3-T MRI Systems and Integrated PET/CT for Non-Small Cell Lung Cancer.
    Ohno Y; Takeshi Y; Takenaka D; Koyama H; Aoyagi K; Yui M
    AJR Am J Roentgenol; 2020 Nov; 215(5):1191-1198. PubMed ID: 32960670
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance Comparison Between
    Kishida Y; Seki S; Yoshikawa T; Itoh T; Maniwa Y; Nishimura Y; Ohno Y
    AJR Am J Roentgenol; 2018 Jul; 211(1):185-192. PubMed ID: 29667886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
    Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant pleural mesothelioma: initial experience in integrated (18)F-FDG PET/MR imaging.
    Schaarschmidt BM; Sawicki LM; Gomez B; Grueneisen J; Hoiczyk M; Heusch P; Buchbender C
    Clin Imaging; 2016; 40(5):956-60. PubMed ID: 27232931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
    Kitajima K; Doi H; Kuribayashi K
    Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal gross tumor volume definition in lung-sparing intensity modulated radiotherapy for pleural mesothelioma: an in silico study.
    Botticella A; Defraene G; Nackaerts K; Deroose CM; Coolen J; Nafteux P; Peeters S; Ricardi U; De Ruysscher D
    Acta Oncol; 2016 Dec; 55(12):1450-1455. PubMed ID: 27732127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
    Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
    Krüger S; Pauls S; Mottaghy FM; Buck AK; Schelzig H; Hombach V; Reske SN
    Nuklearmedizin; 2007; 46(6):239-43. PubMed ID: 18084678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K; Kuribayashi K; Minami T; Yokoyama H; Nakamura A; Hashimoto M; Kijima T; Hasegawa S; Kaida H; Yamakado K
    Oncotarget; 2024 Jun; 15():408-417. PubMed ID: 38900646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the best way to diagnose and stage malignant pleural mesothelioma?
    Zahid I; Sharif S; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.